$11.940
+0.382 (+3.20%)Al cierre
Noticias de VIR
Eventos de VIR
Vir Biotechnology Appoints Dr. Suzanne Topalian to Board of Directors
Vir Biotechnology announced the appointment of Suzanne Topalian, M.D., to its Board of Directors. Dr. Topalian is the Bloomberg-Kimmel Professor of Cancer Immunotherapy at the Johns Hopkins University School of Medicine and serves as Associate Director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy and Director Melanoma/Skin Cancer Program in the Kimmel Cancer Center at Johns Hopkins.
Spero Therapeutics Appoints New Executives
Spero Therapeutics (SPRO) announced the appointments of Amy Rock as chief regulatory and quality officer and Dae Gon Ha as senior VP, corporate development. The company also announced that Timothy Keutzer, COO, will retire from Spero effective December 31. Following Keutzer's retirement, his responsibilities will be assumed by other members of Spero's executive leadership team. Most recently, Rock served as senior VP, regulatory sciences at Vir Biotechnology (VIR).
Vir Biotechnology Collaborates with Gilead to Develop Novel T-Cell Engagers
Vir Biotechnology (VIR) announced a collaboration and license agreement with Gilead (GILD) to discover and engineer three novel PRO-XTEN dual-masked T-cell engager, TCE, development candidates targeting selected solid tumor-associated antigens. Gilead will have an exclusive license to develop and commercialize the novel TCEs. Through this collaboration, Vir Biotechnology will apply its deep expertise in TCE discovery and protein engineering, its proprietary dAIsY platform for rapid, multiparameter optimization of high-quality TCEs and the universal PRO-XTEN masking technology.
Vir Biotechnology Receives FDA Fast Track Designation
Vir Biotechnology (VIR) announced that the U.S. Food and Drug Administration, FDA, granted Fast Track designation, FTD, to VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, TCE, for the treatment of late-line metastatic castration-resistant prostate cancer, mCRPC. VIR-5500 is being co-developed by Astellas Pharma (ALPMY) and Vir Biotechnology through a global strategic collaboration. "Receiving Fast Track designation reflects the potential of VIR-5500 to address an area of serious unmet need in late-line mCRPC and the strong momentum we have achieved with Astellas as we prepare to enter pivotal Phase 3 development in 2027," said Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology. "We look forward to working with the FDA to rapidly advance the development of VIR-5500 for people living with mCRPC."
Vir Biotechnology Appoints Dr. David Liu as Chief Medical Officer
Vir Biotechnology (VIR) announced the appointment of David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 12, 2026. Dr. Liu will be responsible for leading the clinical development, medical affairs and regulatory affairs functions. Liu joins Vir Biotechnology from Nuvation Bio (NUVB), where he served as CMO.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.